# MMJ International Holdings Seeks Injunction to Halt CMS CBD Program > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/legal-challenges-institutional-cbd-programs-patient-access/ > **Published:** 2026-04-13T07:18:14-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:23:46-04:00 > **Clinical Summary:** Explore how legal challenges institutional CBD programs affect patient access and clinical care continuity in the CMS CBD program injunction case. --- ✦ New CED Clinical Relevance  #70Notable Clinical Interest  Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News  |  CED Clinic CbdAccessRegulatoryLegal[Healthcare Policy](https://cedclinic.com/cannabis-legalization-in-canada-new-opportunities/) Why This Matters Legal challenges to institutional CBD programs can disrupt patient access and create uncertainty for clinicians implementing cannabinoid therapies. Understanding regulatory vulnerabilities helps providers anticipate potential access interruptions and develop contingency care plans. Clinical Summary MMJ International Holdings has filed for an injunction against the CMS CBD program, though specific details of the legal challenge are not provided in the available summary. Corporate legal disputes over cannabis programs often involve licensing, market access, or regulatory compliance issues. Such challenges can temporarily or permanently affect program operations and patient access to specific [CBD products](https://cedclinic.com/fda-warning-on-cbd-products/) or services. Dr. Caplan’s Take “I’ve seen promising patient programs get derailed by corporate legal battles that have nothing to do with clinical outcomes. When institutional access is threatened, we need backup protocols ready.” Clinical Perspective 🧠 Clinicians relying on institutional CBD programs should maintain awareness of legal challenges that could affect patient access. Consider identifying alternative CBD sources and preparing patients for potential program interruptions. Document clinical responses carefully to support continuity of care regardless of program status. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20MMJ%20International%20Holdings%20Seeks%20Injunction%20to%20Halt%20CMS%20CBD%20Program%20-%20Morningsta...%20%40drcaplan&url=https%3A//www.morningstar.com/news/accesswire/1156895msn/mmj-international-holdings-seeks-injunction-to-halt-cms-cbd-program)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A//www.morningstar.com/news/accesswire/1156895msn/mmj-international-holdings-seeks-injunction-to-halt-cms-cbd-program)[🦥 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20MMJ%20International%20Holdings%20Seeks%20Injunction%20to%20Halt%20CMS%20CBD%20Program%20-%20Morningsta...%20--%20via%20%40drcaplan.bsky.social%20https%3A//www.morningstar.com/news/accesswire/1156895msn/mmj-international-holdings-seeks-injunction-to-halt-cms-cbd-program)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://www.morningstar.com/news/accesswire/1156895msn/mmj-international-holdings-seeks-injunction-to-halt-cms-cbd-program](https://www.morningstar.com/news/accesswire/1156895msn/mmj-international-holdings-seeks-injunction-to-halt-cms-cbd-program) Table of Contents - [FAQ](#FAQ)[What is the clinical relevance rating for this cannabis news?](#What_is_the_clinical_relevance_rating_for_this_cannabis_news) - [What type of cannabis-related topics does this article cover?](#What_type_of_cannabis-related_topics_does_this_article_cover) - [Why is this article marked as “New”?](#Why_is_this_article_marked_as_8220New8221) - [Who is the target audience for this cannabis news?](#Who_is_the_target_audience_for_this_cannabis_news) - [What should healthcare professionals do with this information?](#What_should_healthcare_professionals_do_with_this_information) - [Related](#Related) ## FAQ #### What is the clinical relevance rating for this cannabis news? This article has been assigned CED Clinical Relevance #70, which indicates “Notable Clinical Interest.” This rating suggests the content contains emerging findings or policy developments that healthcare professionals should monitor closely. #### What type of cannabis-related topics does this article cover? Based on the tags, this article covers CBD, access issues, regulatory matters, and legal aspects of cannabis. These are key areas that impact clinical practice and [patient care](https://cedclinic.com/cannabis-cardiovascular-risk-impact/) in [medical cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/). #### Why is this article marked as “New”? The “New” designation indicates this is recently published content that provides updated information on cannabis-related developments. Fresh content is particularly important in the rapidly evolving cannabis regulatory and clinical landscape. #### Who is the target audience for this cannabis news? This content is published by CED Clinic and appears to be targeted at healthcare professionals and clinicians. The clinical relevance rating system suggests it’s designed for medical practitioners working with cannabis treatments. #### What should healthcare professionals do with this information? Given the “Notable Clinical Interest” rating, healthcare professionals should monitor these developments closely as they may impact clinical practice. The emerging findings or policy changes discussed could affect how cannabis treatments are prescribed or accessed by patients. [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Biopharma Company Joins Lawsuit Over CMS Hemp Pilot – EMJ](https://cedclinic.com/cms-hemp-pilot-program-lawsuit/) Learn about another legal challenge involving the CMS hemp pilot program and its implications for [cannabis industry](https://cedclinic.com/cannabis-mold-contamination-risks-recall-safety/) stakeholders. [Read More](https://cedclinic.com/cms-hemp-pilot-program-lawsuit/) [Medicinal Cannabis Crackdowns Are Actually Working – Medical Republic](https://cedclinic.com/medicinal-cannabis-crackdowns-impact-access/) Explore how regulatory crackdowns are shaping the medicinal cannabis landscape and affecting patient access. [Explore Insights](https://cedclinic.com/medicinal-cannabis-crackdowns-impact-access/) [Texas Hemp Lawsuit Challenges THC Rules as Backdoor Ban](https://cedclinic.com/texas-hemp-lawsuit-challenges-thc-rules/) Understand the legal battles challenging THC regulations and their impact on hemp and cannabis programs. [Learn More](https://cedclinic.com/texas-hemp-lawsuit-challenges-thc-rules/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).